ストックスクリーナーアプリを入手
7.86
0.38%
0.03
アフターアワーズ：
7.86
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews
North Carolina biotech sues to block copies of $400M drug - The Business Journals
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance
Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St
(BCRX) Technical Data - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News Today
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - BioCentury
BioCryst CFO resigns, search for successor begins - Investing.com India
BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks
Where are the Opportunities in (BCRX) - Stock Traders Daily
Rhumbline Advisers Has $2.33 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst stock holds $18 target, JMP bullish on trial results By Investing.com - Investing.com Canada
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? - MSN
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Wedbush Initiates Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
Analysts Set Expectations for BCRX Q1 Earnings - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down Following Weak Earnings - MarketBeat
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know - MSN
3.70%
0.05%
大文字化:
|
ボリューム (24 時間):